Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets shed their morning gains
Thu, 25 Nov 01:30 pm

Profit booking led the Indian markets to shed their gains of the first half and move towards the dotted line during the previous hour of trade. Currently stocks from the realty, metal and capital goods spaces are main losers. IT and healthcare stocks are however trading firm. Currently there are 2.1 losers for ever gainer on the overall BSE.

The BSE-Sensex and the NSE-Nifty indices are trading lower by about 10 points each. The pessimism has been extended towards midcap and smallcap stocks as the BSE-Midcap and BSE-Smallcap indices are trading lower by about 1% each. The rupee is trading at 45.64 to the US dollar.

Pharma stocks are currently trading mixed with Ranbaxy and Piramal Healthcare trading weak while Sun Pharmaceuticals and Lupin are trading firm. The stock of Sun Pharmaceuticals is trading firm on the back of the announcement of its receiving a tentative approval from the US FDA (Food and Drug Administration) to market a generic version of 'Cymbalta' in the American market. This drug is used to treat anxiety and depression. The company's US subsidiary has received this tentative approval for the drug in strengths of 20 mg, 30 mg and 60 mg. 'Cymbalta' is a registered trademark of Eli Lilly & Company. Considering that the annual sales of these capsules stands at nearly US$ 3 bn (approximately Rs 135 bn) in the US alone, this is a positive development for Sun Pharmaceuticals as it will augment its revenues from the highly competitive US generics market.

Auto stocks are trading mixed with Bajaj Auto and TVS Motor leading the gains while Maruti Suzuki, Ashok Leyland and M&M are facing selling pressure. A leading business daily has reported that India’s second largest motorcycle maker Bajaj Auto plans to manufacture commercial vehicles as well on a new platform it is developing in Waluj, Maharashtra, for its small car project. The company intends to develop a multidimensional platform through which it can manufacture commercial vehicles and passenger cars. The Waluj plant is being set up at a cost of Rs 5 bn. Of this, Rs 2.3 to 2.5 bn has been earmarked for investment in the current fiscal.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets shed their morning gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.